Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Healthtrust
Covington
QuintilesIMS
Mallinckrodt
Medtronic
Farmers Insurance
Daiichi Sankyo
Express Scripts

Generated: July 17, 2018

DrugPatentWatch Database Preview

Desoximetasone - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for desoximetasone and what is the scope of desoximetasone freedom to operate?

Desoximetasone
is the generic ingredient in three branded drugs marketed by Actavis Mid Atlantic, Akorn, Fougera Pharms, Groupe Parima Inc, Lupin Atlantis, Perrigo New York, Taro Pharm Inds Ltd, Rising Pharms Inc, Altana, G And W Labs Inc, Glenmark Generics, Novel Labs Inc, Perrigo Israel, Teligent Pharma Inc, Zydus Pharms Usa Inc, and Taro Pharms, and is included in thirty-six NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Desoximetasone has four patent family members in four countries.

There are seven drug master file entries for desoximetasone. Eighteen suppliers are listed for this compound.
Pharmacology for desoximetasone
Medical Subject Heading (MeSH) Categories for desoximetasone
Synonyms for desoximetasone
(11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
17-Deoxymethansone
17-Desoximethasone
382-67-2
382D672
4E07GXB7AU
9-Fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
9alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1.4-pregnadiene-3,20-dione
9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
A 41-304
A 41304
A-41-304
AB2000738
AC1NSJXQ
AKOS030254657
AS-15787
BDBM50103622
BRN 2228097
C-55186
CAS-382-67-2
CCG-101120
CHEBI:691037
CHEMBL1766
CS-3002
CTK8F9086
D03697
D0CZ1Q
DB00547
Deoxymethasone
Desossimetasone
Desossimetasone [DCIT]
Desoximetason
Desoximetasona
Desoximetasona [INN-Spanish]
Desoximetasone (USP/INN)
Desoximetasone [USAN:USP:INN:BAN]
Desoximetasonum
Desoximetasonum [INN-Latin]
desoximethasone
Desoxymetasone
Desoxymethasone
DSSTox_CID_25647
DSSTox_GSID_45647
DSSTox_RID_81025
DTXSID3045647
EINECS 206-845-3
Esperson
Flubason
GTPL7067
HMS2052C15
HMS2236H07
HOE 304
HOE-304
HY-17570
Ibaril
MLS000028654
MLS001076073
MLS001424230
MolPort-003-941-111
NC00370
NCGC00023648-03
NCGC00023648-04
Opera_ID_52
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11beta,16alpha)-
Q-200938
Q790
R 2113
R-2113
SC-46986
SCHEMBL4214
SMR000058856
Stiedex
Topicort
Topicort (TN)
Topicort Emollient (TN)
Topicort LP
Topisolon
Tox21_110889
Tox21_110889_1
UNII-4E07GXB7AU
VWVSBHGCDBMOOT-IIEHVVJPSA-N
ZINC4212854

US Patents and Regulatory Information for desoximetasone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn DESOXIMETASONE desoximetasone CREAM;TOPICAL 203787-001 Jan 6, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone OINTMENT;TOPICAL 018763-001 Sep 30, 1983 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone OINTMENT;TOPICAL 074286-001 Jun 7, 1996 AB RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone CREAM;TOPICAL 017856-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for desoximetasone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,038 Composition and method for treatment of psoriasis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Merck
Baxter
Cantor Fitzgerald
Fuji
Fish and Richardson
Dow
Cerilliant
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.